Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
AssigneeResearch Cancer Institute of America
InventorMohammed Amin Nezami
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one modulator selected from quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone.
Claims15
A pharmaceutical composition for treatment of a neoplasm, the pharmaceutical composition comprising:
- synergistically effective amounts of:
- at least one anti-cancer agent, wherein the at least one anti-cancer agent is oral cyclophosphamide, and wherein the amount of cyclophosphamide is about 50 mg to about 150 mg;
- a first anti-cancer response modulator, wherein the first anti-cancer response modulator is intravenous quercetin;
- and
- a second anti-cancer response modulator, wherein the second anti-cancer response modulator is intravenous sodium phenyl butyrate (SPB).
A kit for treatment of a neoplasm, wherein the kit comprises a pharmaceutical composition comprising:
- synergistically effective amounts of:
- at least one anti-cancer agent, wherein the at least one anti-cancer agent is oral cyclophosphamide, and wherein the amount of cyclophosphamide is about 50 mg to about 150 mg;
- a first anti anti-cancer response modulator, wherein the first anti-cancer response modulator is intravenous quercetin;
- and
- a second anti anti-cancer response modulator, wherein the second anti-cancer response modulator is intravenous SPB.
A method of treatment of a neoplasm in a patient in need thereof, the method comprising:
- identifying a patient with a neoplasm;
- administering a pharmaceutical composition comprising:
- synergistically effective amounts of:
- at least one anti-cancer agent, wherein the at least one anti-cancer agent is cyclophosphamide, and wherein the cyclophosphamide is administered orally at a dose of about 3 mg/kg to about 50 mg/kg;
- a first anti-cancer response modulator, wherein the first anti-cancer response modulator is intravenous quercetin;
- and
- a second anti anti-cancer response modulator, wherein the second anti-cancer response modulator is intravenous SPB.
Dependencies are inferred from the claim text.